- Tim Cook Should Tell Congress to Kiss His Ass
- Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma
- 5 Worst Home Renovation Projects
- How the New York Hedge Funds Lost Their Shirts on Tesla
- What You Wear to the Office Still Matters
Article
Options Trade Into Ziopharm's Sarcoma Drug Study Results
Options expert Tony Pelz says options are the best way to trade Ziopharma's looming palifosamide data.
11:00AM 02/26/13
Article
Dynavax Options Trade for Heplisav FDA Approval Decision
Options expert Tony Pelz offers investors a way to use options to trade Dynavax's upcoming FDA decision.
08:30AM 02/12/13
Article
Alexza Pharma: Premium Selling Options Strategy
A new options trade for Alexza going into an FDA drug approval decision.
11:27AM 12/12/12
Article
Amicus: Bullish Options Trade Into Clinical Trial Catalysts
Contributor Tony Pelz offers an options trade for those who believe Amicus shares are going higher.
09:05AM 12/04/12
Article
Dynavax: Speculative Upside Options Trade
How to use options to play a possible run-up in Dynavax prior to the FDA's approval decision.
07:31AM 11/20/12
Article
Exelixis: New Drug Approval Options Trade
Options wizard Tony Pelz suggests another way to trade Exelixis's FDA drug approval decision.
08:00AM 11/06/12
Article
Eli Lilly: Bearish Options Trade
Tony Pelz offers a short-term options trade to take advantage of end-of-year selling in Eli Lilly.
10:01AM 11/01/12
Article
Ziopharm: Options Trade for Phase III Data
How to play the high-risk release of results from Ziopharm's phase III study.
08:30AM 10/22/12
Article
How to Hedge Profits in Sarepta Therapeutics
Options guru Tony Pelz offers options trades for those who want to protect their Sarepta profits.
09:00AM 10/15/12
Article
NPS Pharma: Bullish Options Trade Into the Gattex FDA Panel
Biotech options expert Tony Pelz recommends a bullish options trade for the Oct. 16 Gattex FDA panel.
08:00AM 10/08/12